We offer a subscription service with a nightly email, research reports, SMS alerts, education, group chat and more. Click here to see our offerings and plans.
- Headquartered in San Carlos CA, Atreca is a clinical-stage biotech company focused on the immunotherapy space
- For an overview of BCEL pipeline, click here
- On 7/06/20 the company partnered with Xencore to develop and commercialize novel T Cell engaging bispecific antibodies
- On 7/16/20 the company announced a $125 million offering at $16 per share
- In response to this news, shares receded from the $20s in July to 52-week lows of $8.25 within several months
- During this time, the company has been busy at conferences; PacGrow, H.C. Wainwright & Morgan Stanley, SITC, IO, Stifel, and Evercore